In order to test their potential tumor suppressor role, we performed a viability assay on breast cancer cell lines representing different clinical subtypes (TNBC, ER+ and HER2-overexpressed) where miR-564 and miR-490 were ectopically expressed. Here, ERBB2 is linked to breast carcinoma.